Martin Huličiak

Mr. Martin Huličiak

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MHMartin Huličiak
Martin Huličiak
Ivan VokřálIvan Vokřál
Ivan Vokřál
Ondrej HolasOndrej Holas
Ondrej Holas
OMOndřej Martinec
Ondřej Martinec
František ŠtaudFrantišek Štaud
František Štaud
LČLukáš Červený
Lukáš Červený
The inhibition of P-glycoprotein (ABCB1) could lead to increased drug plasma concentrations and hence increase drug toxicity. The evaluation of a drug’s ability to inhibit ABCB1 is complicated by the presence of several transport-competent sites within the ABCB1 binding pocket, making it difficult to select appropriate substrates. Here, we investigate the capacity of antiretrovirals and direct-acting antivirals to inhibit the ABCB1-mediated intestinal efflux of [3H]-digoxin and compare it with our previous rhodamine123 study. At concentrations of up to 100 µM, asunaprevir, atazanavir, daclatasvir, darunavir, elbasvir, etravirine, grazoprevir, ledipasvir, lopinavir, rilpivirine, ritonavir, saquinavir, and velpatasvir inhibited [3H]-digoxin transport in Caco-2 cells and/or in precision-cut intestinal slices prepared from the human jejunum (hPCIS). However, abacavir, dolutegravir, maraviroc, sofosbuvir, tenofovir disoproxil fumarate, and zidovudine had no inhibitory effect. We thus found that most of the tested antivirals have a high potential to cause drug–drug interactions on intestinal ABCB1. Comparing the Caco-2 and hPCIS experimental models, we conclude that the Caco-2 transport assay is more sensitive, but the results obtained using hPCIS agree better with reported in vivo observations. More inhibitors were identified when using digoxin as the ABCB1 probe substrate than when using rhodamine123. However, both approaches had limitations, indicating that inhibitory potency should be tested with at least these two ABCB1 probes.

9 November 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MŠMichaela Šadibolová
Michaela Šadibolová
MHMartin Huličiak
Martin Huličiak
LSLucie Raisová Stuchlíková
Lucie Raisová Stuchlíková
MHMartin Horní
Martin Horní
LPLukáš Prchal
Lukáš Prchal
IBIva Boušová
Iva Boušová
6-prenylnaringenin (6-PN) has recently attracted attention for its chemopreventive, cytotoxic, and analgesic activities; however, information on its pharmacokinetic properties remains limited, making it difficult to interpret its biological effects. This study thus investigated the metabolism of 6-PN in humans, mice, and rats, as well as its intestinal transport and interaction with ABCB1 in humans. 6-PN (10 µM) was efficiently metabolized predominantly via phase II conjugation across all studied species. Overall, 13 phase I/II metabolites were detected, including novel sulfoglucuronide diconjugates not previously reported for structurally similar hop prenylflavonoids. Importantly, murine hepatic metabolism of 6-PN more closely resembled its human hepatic biotransformation profile, favoring murine over rat models in pharmacokinetics studied. Further, 6-PN showed appreciable transport in the absorptive AB direction, while the observed BA-over-AB asymmetry was not reduced by ABCB1/ABCG2 inhibition, although it modulated ABCB1 substrate transport in a model- and substrate-dependent manner. Overall, these data indicate that 6-PN can undergo transepithelial transport in the absorptive direction, whereas extensive phase II metabolism may substantially shape its bioavailability.